Equities Analysts Offer Predictions for Tetraphase Pharmaceuticals Inc’s FY2017 Earnings (TTPH)
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) – Analysts at B. Riley issued their FY2017 EPS estimates for Tetraphase Pharmaceuticals in a research note issued to investors on Monday. B. Riley analyst M. Kumar anticipates that the biopharmaceutical company will earn ($2.70) per share for the year. B. Riley currently has a “Buy” rating and a $11.00 target price on the stock. B. Riley also issued estimates for Tetraphase Pharmaceuticals’ FY2018 earnings at ($2.01) EPS.
TTPH has been the subject of several other research reports. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, December 5th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Tetraphase Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $14.46.
Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Tetraphase Pharmaceuticals by 77.6% during the 4th quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock worth $3,733,000 after purchasing an additional 258,908 shares during the last quarter. AXA lifted its position in shares of Tetraphase Pharmaceuticals by 7.1% during the 4th quarter. AXA now owns 216,337 shares of the biopharmaceutical company’s stock worth $1,363,000 after purchasing an additional 14,400 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Tetraphase Pharmaceuticals during the 4th quarter worth $376,000. BlackRock Inc. lifted its position in shares of Tetraphase Pharmaceuticals by 21.2% during the 4th quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock worth $25,479,000 after purchasing an additional 707,296 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its position in shares of Tetraphase Pharmaceuticals by 28.5% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 505,000 shares of the biopharmaceutical company’s stock worth $3,182,000 after purchasing an additional 112,000 shares during the last quarter. 58.28% of the stock is owned by institutional investors and hedge funds.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director L Patrick Gage acquired 3,880 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares in the company, valued at approximately $250,776. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.